Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant Tuberculosis

US FDA's Antimicrobial Drugs Advisory Committee made clear that its positive 14-4 approval vote was supportive of the TB Alliance's pretomanid as part of a regimen for treatment-resistant tuberculosis since the role of each active ingredient in the combination is not adequately understood. 

FDA Advisory Committee Feature image
The Antimicrobial Drugs Advisory Committee voted 14-4 supporting approval of the pretomanid regimen.

The US Food and Drug Administration's Antimicrobial Drugs Advisory Committee endorsed the approval of the Global Alliance for TB Drug Development'spretomanid as part of a treatment-resistant tuberculosis regimen in a 14-4 vote, although panelists made clear at the 6 June meeting that they supported the regimen rather than the individual molecule.

Pretomanid is a nitroimidazooxazine antimycobacterial drug which the TB Alliance is developing as part of an oral combination with

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers